Experimental Senolytic Peptide

FOXO4-DRI

FOXO4 D-Retro-Inverso • Preclinical Senescent-Cell Research

FOXO4-DRI is an experimental peptide designed to disrupt the FOXO4-p53 interaction in certain senescent cells, redirecting p53 toward apoptosis. Its reported benefits come from cell and animal studies; no validated human anti-aging dose, safety profile, or clinical protocol exists.

Senescent Cells FOXO4-p53 Pathway Preclinical Evidence No Human Trials

Protocol Snapshot

FOXO4-DRI Quick Reference

Verified Vendors

FOXO4-DRI

Compare Verified Vendors

Current price and availability
Price per mg and vial-size comparison
Testing and fulfillment details

Compare

View Price Index

Low-Dose Protocol

250–500mcg

Anecdotal daily escalation over 16 weeks.

Pulse Protocol

3mg EOD

Three anecdotal injections over six days.

Class

Senolytic

Review the full protocol details below.

Primary Target

FOXO4-p53

Review the full protocol details below.

Peptide Grade

GradeD

A bold senolytic concept with striking preclinical interest, but virtually no human evidence, uncertain selectivity, and major theoretical safety concerns keep confidence low.

Research Community Safety

Foundation

Research context, mechanisms, and practical use cases

What is FOXO4-DRI?

FOXO4-DRI is a synthetic D-retro-inverso peptide developed to target a survival mechanism used by some senescent cells. Senescent cells are damaged, stressed, or aged cells that have permanently stopped dividing but remain biologically active.

As senescent cells accumulate, they can release inflammatory cytokines, growth factors, and tissue-remodeling proteins known collectively as the senescence-associated secretory phenotype, or SASP. These signals may impair surrounding tissue and contribute to age-related dysfunction.

In certain senescent cells, FOXO4 helps retain the tumor-suppressor protein p53 inside the nucleus. FOXO4-DRI competes with this interaction, allowing p53 to leave the nucleus and move toward the mitochondria, where it can trigger caspase-dependent apoptosis.

The D-retro-inverso design reverses the peptide sequence and uses D-amino acids. This approach is intended to improve resistance to enzymatic degradation while preserving the spatial characteristics needed for target binding.

What the Original Research Found

In the original 2017 study, FOXO4-DRI selectively reduced the viability of senescent cells in laboratory models and improved fur density, activity, and kidney-function measures in aged or accelerated-aging mice. It also reduced aspects of doxorubicin-related toxicity in mice.

FOXO4-DRI has not been validated as a human anti-aging therapy. The mechanism is compelling, but efficacy, pharmacokinetics, immunogenicity, long-term safety, and optimal dosing remain unknown in humans.

Potential FOXO4-DRI Benefits

These are preclinical research findings, not established human treatment outcomes.

Senescent Cell Clearance

FOXO4-DRI induced apoptosis preferentially in certain senescent cell models by disrupting FOXO4-p53 binding. Senescent cells are heterogeneous, so the peptide may not target every senescent cell type equally.

Tissue Homeostasis

The original mouse research reported improvements in fur density, voluntary activity, and kidney-function markers after short-course treatment.

SASP & Inflammation Research

Clearing senescent cells may reduce SASP-related inflammatory signaling. Later animal studies reported reductions in selected senescence and inflammatory markers.

Pulmonary Fibrosis Research

In bleomycin-induced mouse models, FOXO4-DRI reduced senescent myofibroblasts, collagen deposition, SASP expression, and fibrosis-related changes. This does not establish a human pulmonary-fibrosis treatment.

Leydig Cell & Testosterone Research

In aged mice, FOXO4-DRI removed senescent Leydig cells, improved the testicular microenvironment, and partially alleviated age-related reductions in testosterone secretion.

Chemotoxicity Research

The original mouse study reported protection against aspects of doxorubicin-induced toxicity by targeting treatment-induced senescent cells. This is not evidence that self-administration during chemotherapy is safe.

Protocol Planning

Dosing, cycling, and preparation

FOXO4-DRI Dosing Protocol

No established human dose exists. Both schedules below are anecdotal community protocols and have not been validated in human trials for safety, pharmacokinetics, senescent-cell selectivity, or long-term outcomes.

Daily Low-Dose Approach

Weeks 1–4

250mcg subcutaneously once daily

Weeks 5–8

375mcg subcutaneously once daily

Weeks 9–16

500mcg subcutaneously once daily

Status

Unvalidated long-duration community protocol

Pulse Approach

Dose

3mg subcutaneously

Frequency

Every other day

Cycle

Three injections over six days

Repeat

Anecdotally repeated 1–3 times per year

Important Dose Context

Animal doses cannot be converted directly into a safe human dose. Online schedules differ dramatically because there is no human dose-ranging study, no established therapeutic window, and no validated biomarker showing when enough senescent cells have been cleared.

FOXO4-DRI Reconstitution

The following concentration mathematics uses a 10mg vial with 2mL of bacteriostatic water. It does not establish that any listed dose is safe or effective.

10mg Vial

Vial Size

10mg

BAC Water

2mL

Concentration

5mg/mL

250mcg

5 units on a U-100 insulin syringe

500mcg

10 units on a U-100 insulin syringe

3mg

60 units on a U-100 insulin syringe

Reconstitution Calculator

Handling Notes

Mixing

Add bacteriostatic water to the vial.

Do Not

Do not shake aggressively.

Storage

Refrigerate after reconstitution and follow supplier-specific stability data.

Quality

Identity, purity, sterility, and endotoxin testing are major concerns with research products.

Anecdotal Data Points

Community-reported outcomes and recurring patterns

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

A small number of users report better energy, recovery, appearance, or inflammation, but these claims are inconsistent and cannot be separated from placebo effects or concurrent treatments.

Negative or Neutral Reports

Injection-site burning, itching, redness, or swelling is one of the most commonly discussed complaints.
Many users report no immediately noticeable effect.
Some users report transient fatigue, headache, or flu-like sensations after dosing.

Stacking & Synergy

Potential FOXO4-DRI pairings and tracking context

FOXO4-DRI Stacking & Synergy

FOXO4-DRI + Epitalon

Longevity communities describe this as a theoretical “clear and rebuild” sequence: FOXO4-DRI for senescent-cell clearance and Epitalon for telomere or pineal pathways. No human study has evaluated the combination.

FOXO4-DRI + SS-31

This pairing is intended to combine senescent-cell clearance with mitochondrial support. The mechanisms are different, but combination safety and efficacy are unknown.

Follow-Up with MOTS-c or NAD+

Some users transition to MOTS-c or NAD+ after a senolytic phase to support cellular energy metabolism. This sequencing strategy is speculative.

Other Senolytics

Combining FOXO4-DRI with fisetin, quercetin, dasatinib, rapamycin, or other experimental senolytics may increase unpredictable effects. No validated combination protocol exists.

There are no established drug-interaction studies for FOXO4-DRI. Absence of documented interactions does not mean combinations are safe.

Free with login

Track in Journal

Track FOXO4-DRI with the markers that matter most for this compound.

Dose, injection timing, cycle day, and source.
Energy, fatigue, recovery, and functional changes.
Injection-site response, headache, inflammation, and unexpected effects.

Start Tracking

Safety Notes

Side effects, contraindications, and precautions

FOXO4-DRI Side Effects

The original mouse experiments described FOXO4-DRI as relatively well tolerated under the tested conditions, without the thrombocytopenia associated with some other experimental senolytics. Those findings cannot establish human safety.

No completed human clinical safety program has established acute toxicity, immune response, organ effects, reproductive risk, cancer risk, or the consequences of repeated dosing.

Anecdotal / Immediate Reports

Injection-site burning, itching, redness, or swelling.
Fatigue or reduced energy.
Headache or flu-like sensations.
Possible allergic or inflammatory reactions.

Unknown / Theoretical Risks

Immune responses or neutralizing antibodies with repeated exposure.
Off-target apoptosis in healthy or beneficial cell populations.
Unexpected effects from manipulating the FOXO4-p53 pathway.
Contamination, endotoxin exposure, or incorrect concentration in research products.

FOXO4-DRI Contraindications and Precautions

Do Not Use If You Have

Pregnancy or breastfeeding, because no developmental or reproductive safety data exists.
Active cancer, suspected malignancy, or current chemotherapy or radiation treatment without explicit oncology supervision.
Known hypersensitivity to FOXO4-DRI or any formulation component.

Use Extreme Caution With

A history of cancer or a condition involving abnormal cell growth.
Bone-marrow disorders, low platelet counts, immune disorders, or immunosuppressive treatment.
Severe kidney or liver impairment.
Other senolytic drugs, peptides, or research compounds.

p53-Pathway Concern

FOXO4-DRI intentionally alters the FOXO4-p53 interaction. p53 is central to DNA-damage responses, cell-cycle control, tumor suppression, and apoptosis. The long-term consequences of repeatedly manipulating this pathway in humans are unknown.

Drug Interactions

No well-established interaction profile exists. Online warnings involving rapamycin, quercetin, corticosteroids, or other senolytics are best treated as absence-of-data precautions rather than proven interaction rules.

Regulatory Status

FOXO4-DRI is not FDA approved for any indication and has no established human prescribing information, validated clinical dose, approved manufacturing standard, or confirmed therapeutic use.

FINAL VERDICT

Peptide Protocol's Opinionated Opinion

This is not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

We view FOXO4-DRI as an aggressive senolytic peptide with interesting potential on paper. Some experienced users report better energy and reduced inflammation after targeted cycles. However, we are deliberately staying away from it and will not be testing FOXO4-DRI in-house at peptideprotocols.app.

The safety profile is risky and not well-established for long-term or repeated use. Our main concern is the possibility of it clearing out useful cells along with senescent ones — that kind of non-selective action makes us uncomfortable. It requires very careful support protocols and is best left to advanced users who fully understand the risks.

Potent for those willing to experiment at the edge, but too uncertain and aggressive for our recommendations. We suggest skipping it unless you have a very specific, well-researched reason and medical oversight.